These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37403288)

  • 21. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.
    Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X
    Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying bioactive phytoconstituents as C-terminal Src kinase inhibitors: a virtual screening and molecular simulation approach.
    Elfaki EM; Alhassan HH; Kamal M; Al-Enazi MM; Rub MA; Asiri AM; Ali M; Marwani HM; Alharethi SH; Alotaibi MM; Azum N
    J Biomol Struct Dyn; 2023; 41(22):13415-13424. PubMed ID: 36752377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of natural product-based effective inhibitors of spleen tyrosine kinase (SYK) through virtual screening and molecular dynamics simulation approaches.
    Ali T; Anjum F; Choudhury A; Shafie A; Ashour AA; Almalki A; Mohammad T; Hassan MI
    J Biomol Struct Dyn; 2024 Apr; 42(7):3459-3471. PubMed ID: 37261484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products.
    Park H; Lee S; Hong S
    J Nat Prod; 2016 Feb; 79(2):293-9. PubMed ID: 26807861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potential inhibitors of tropomyosin receptor kinase B targeting CNS-related disorders and cancers.
    Hakami MA; Alotaibi BS; Hazazi A; Shafie A; Alsaiari AA; Ashour AA; Anjum F
    J Biomol Struct Dyn; 2024 Apr; 42(6):2965-2975. PubMed ID: 37184150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
    Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L
    Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
    Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT
    PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
    Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
    J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.
    Wu TS; Lin WH; Tsai HJ; Hsueh CC; Hsu T; Wang PC; Lin HY; Peng YH; Lu CT; Lee LC; Tu CH; Kung FC; Shiao HY; Yeh TK; Song JS; Chang JY; Su YC; Chen LT; Chen CT; Jiaang WT; Wu SY
    J Med Chem; 2019 Apr; 62(8):3940-3957. PubMed ID: 30968693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
    Kettle JG; Anjum R; Barry E; Bhavsar D; Brown C; Boyd S; Campbell A; Goldberg K; Grondine M; Guichard S; Hardy CJ; Hunt T; Jones RDO; Li X; Moleva O; Ogg D; Overman RC; Packer MJ; Pearson S; Schimpl M; Shao W; Smith A; Smith JM; Stead D; Stokes S; Tucker M; Ye Y
    J Med Chem; 2018 Oct; 61(19):8797-8810. PubMed ID: 30204441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
    Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
    Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
    Zhang Y; Zhang TJ; Tu S; Zhang ZH; Meng FH
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules.
    Vanajothi R; Vedagiri H; Al-Ansari MM; Al-Humaid LA; Kumpati P
    J Biomol Struct Dyn; 2022 May; 40(8):3385-3399. PubMed ID: 33200682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy.
    Hassan MI; Anjum D; Mohammad T; Alam M; Khan MS; Shahwan M; Shamsi A; Yadav DK
    J Biomol Struct Dyn; 2023 Dec; 41(20):10558-10568. PubMed ID: 36495308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
    Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J
    J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enriching Anticancer Drug Pipeline with Potential Inhibitors of Cyclin-Dependent Kinase-8 Identified from Natural Products.
    Zehra ; Hussain A; AlAjmi MF; Ishrat R; Hassan MI
    OMICS; 2024 Sep; 28(9):478-488. PubMed ID: 39149808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unveiling Phytoconstituents with Inhibitory Potential Against Tyrosine-Protein Kinase Fyn: A Comprehensive Virtual Screening Approach Targeting Alzheimer's Disease.
    Alrouji M; Majrashi TA; Alhumaydhi FA; Zari A; Zari TA; Al Abdulmonem W; Sharaf SE; Shahwan M; Anwar S; Shamsi A; Atiya A
    J Alzheimers Dis; 2023; 96(2):827-844. PubMed ID: 37899058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.